Ancor Capital Partners, a Dallas-based private equity firm, has acquired STATinMED Research, a medical technology company in the health economics and outcomes research (HEOR) industry.
The transaction, which was finalised on 7 September, represents Ancor’s largest acquisition to date. Terms of the transaction have not been disclosed.
As one of the world’s leading HEOR companies, STATinMED is transforming the way health care uses real world data to accelerate research and generate evidence that provides enhanced decision-making capabilities for the market. Using their customised research methodologies and a diverse set of data sources, STATinMED draws on millions of data points to develop strategies that deliver better clinical outcomes, higher cost savings and greater value at every stage of the pharmaceutical product lifecycle. STATinMED collaborates with its clients in the pharmaceutical, biotechnology and health information fields to deliver demonstrable results that allow for greater confidence in marketability, pricing strategies, product development, various treatment mixes, economic vitality and cost-effectiveness that ultimately results in the better overall quality of patient care.
Founded in 2007 by Onur Baser, PhD, STATinMED’s interdisciplinary team includes numerous industry specialists that hold advanced degrees or academic positions with prestigious universities and bring expertise in health economics, pharmacoeconomics, clinical or outcomes research, research design, econometrics, statistics and biostatistics. STATinMED has three US locations – Plano, Texas; Ann Arbor, Michigan; and New York, New York.
“Adding STATinMED Research to the Ancor portfolio complements our long-term growth strategy – taking established, successful companies and accelerating their position in the market,” says Vic Keller, managing partner at Ancor Capital Partners. “The HEOR industry is a complex and fast-growing discipline. As the nation’s economy continues to be challenged by escalating health care costs, STATinMED has emerged as one of the primary drivers of innovation whose trusted research influences strategic health care decision-making.
“It is an honour to be part of this extraordinary team of professionals who are doing such important and purposeful work in the health care industry. Dr Baser and his team have done an outstanding job building, growing and executing the vision of STATinMED. Their passion and leadership have instilled a culture of success that has positioned STATinMED to be the preferred partner for the HEOR needs of major pharmaceutical and health care companies. We are excited for the tremendous market opportunities in front of STATinMED and believe that Ancor’s operational expertise and established resources will help propel STATinMED to the next level.”
“We are excited to partner with Ancor as we execute our next phase of growth,” says Baser, founder and chief scientific officer of STATinMED. “We have an incredibly driven culture and are passionate about providing elite services to our customers. I am confident that Ancor’s strategies will align with our vision, and their extensive experience and resources will position STATinMED to capitalise on the opportunities ahead.”
The transaction was led by Keller. Keller joined Ancor Capital Partners in 2017 and brings over 20 years of experience in establishing, growing and optimising businesses. Keller will assume the role of chairman at STATinMED effective immediately.
Ancor partnered with Capital Southwest Corporation, CION Investments, Harbert Management Corporation and Dos Rios Partners to finance the acquisition with senior debt and co-invested equity.
This transaction represents the 52nd investment for Ancor Capital Partners.
